IgA Nephropathy Market
Market Insights on IgA Nephropathy covering sales outlook, demand forecast & up-to-date key trends
IgA Nephropathy Market by Diagnosis, Diseases Type, Systems, Population Type, Route of Administration, Treatment, End Users & Region – Forecast 2023–2033
IgA Nephropathy Market Snapshot
The global IgA nephropathy market is expected to garner a market value of US$ 41.24 Billion in 2023 and is expected to accumulate a market value of US$ 85 Billion by registering a CAGR of 7.5% in the forecast period 2023-2033. Growth of the IgA nephropathy market can be attributed to growing prevalence of kidney diseases amongst different age groups. The market for IgA nephropathy registered a CAGR of 4.8% in the historical period 2017-2022
IgAN is an autoimmune disease that attacks the kidneys. It affects blood filtration in the small blood vessels of the kidneys. It occurs when an abnormal protein damages the filtering unit (glomerulus) inside the kidneys. This, in turn, causes pain leading to patients undertaking different forms of treatments.
|
Report Attribute |
Details |
|
Expected Market Value (2023) |
US$ 41.24 Billion |
|
Anticipated Forecast Value (2033) |
US$ 85 Billion |
|
Projected Growth Rate (2023-2033) |
7.5% CAGR |
Let us know your requirement to get
100% FREE customization
2017-2022 IgA Nephropathy Market Demand Analysis vs. Forecast 2023-2033
According to market research and competitive intelligence provider Future Market Insights- the market for IgA nephropathy reflected a value of 4.8% during the historical period, 2017- 2022.
The increasing cases of COVID-19 have a direct correlation with the growth of kidney-related diseases. For instance, as per a report published in 2021, titled, "Acute Kidney Injury in COVID-19: 90 Days of the Pandemic in a Brazilian Public Hospital," 4–37% of COVID-19 cases involve the kidneys, and acute kidney diseases have an incidence of 50% among hospitalized COVID-19 patients. Thus, it has been found that the COVID-19 virus is having an impact on the kidney of patients, which in turn, is expected to increase the burden of kidney disorders in the near future and fuel the market growth.
The major factors for the growth of the IgA nephropathy market include the increasing incidence of chronic kidney diseases, technological advancements in diagnostic tests for kidney diseases, and the increasing need for early detection. Thus, the market for IgA nephropathy is expected to register a CAGR of 7.5% in the forecast period 2023-2033.
Which are Some Prominent Drivers of IgA Nephropathy Market?
Conventional treatments and approval of medication favouring growth of market
Conventional major treatments to manage IgAN include ACE inhibitors (angiotensin-converting enzyme inhibitors) and ARBs (angiotensin II receptor blockers), to manage symptoms like high blood pressure, etc. Other treatments include corticosteroids, to slow the progression of the disease, and other immunosuppressants like MMF, cyclophosphamide, etc.
TARPEYO (budesonide) delayed release capsules, is the first and only FDA approved drug for the treatment of IgAN. It is indicated for IgAN patients, who at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥ 1.5 g/g. It was approved by the US FDA in December 2021, under accelerated approval pathway, recognizing the urgent need for safe and efficacious therapies.
Availability of therapeutic treatments creating lucrative opportunities for IgA nephropathy market
Tarpeyo: Calliditas Therapeutics AB
Tarpeyo (developed under the project name Nefecon) is a patented oral formulation of a potent and well-known active substance- budesonide for targeted release. The formulation is designed to deliver the drug to the Peyer’s patch region of the lower small intestine, where the disease originates, as per the predominant pathogenesis models. Tarpeyo is derived from the TARGIT technology, which allows the substance to pass through the stomach and intestine without being absorbed and released in a pulse-like fashion only when it reaches the lower small intestine.
In addition to its potent local effect, another advantage of using this active substance is its very low bioavailability, i.e., around 90% of it is inactivated in the liver before it reaches the systemic circulation. This means that a high concentration can be applied locally where needed but with only very limited systemic exposure and side effects.
Sparsentan: Travere Therapeutics, Inc
Sparsentan is a first-in-class, orally active, single-molecule that functions as a high-affinity dual-acting antagonist of both endothelin type A (ETA) and angiotensin II subtype 1 (AT1) receptors which are associated with kidney disease progression.
Endothelin I and angiotensin II leads to decline in kidney function by contributing to inflammation and fibrosis in the kidney, changes to the shape of podocytes, podocyte loss, and increased permeability of the glomerular filtration barrier. Endothelin I and angiotensin II are also vasoconstrictive, meaning they cause a narrowing of blood vessels and an increase in pressure in the glomeruli.
Reimbursement of treatments propelling the growth of IgA nephropathy market
Proactively approaching reimbursement can induce a positive impact both during the early stages of product development and well after product launch. The report considers reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with better market access can be a critical business and price strategy.
To assist patients and their healthcare providers who prescribe Tarpeyo, Calliditas has launched a comprehensive patient support program – Tarpeyo Touchpoints. It is a full-service patient and provider support program designed to accelerate and streamline access to Tarpeyo. It utilizes biologics by McKesson’s Pharmacy Elite model integrated hub and exclusive specialty pharmacy under one roof and is staffed by care navigators and a designated rare pod team (nurses, pharmacists, fulfillment, and distribution team).
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhat are the Challenges Faced by the IgA Nephropathy Market?
Ignorance towards kidney diseases affecting IgA nephropathy market growth
Although the number of people suffering from kidney diseases is high, the unavailability of exact treatment to cure IgA nephropathy is derailing the progress of the market. In addition, lack of awareness of kidney diseases and ignorance is severely hindering the growth of the market. In certain cases, the time taken for approval for medications is too long. This, in turn, is affecting the growth of the IgA nephropathy market.
Region-Wise Insights
Approval of Therapies and Presence of Drug Manufacturers Boosting Market Growth of IgA Nephropathy Market in North America?
Rising awareness of disease and treatment bolstering the market for IgA nephropathy market in North America
In the coming years, IgAN market is set to change due to the rising awareness of the disease, development of diagnostic techniques, and the favorable environment from regulators, for innovative first-in-class curative drugs, as there were no approved therapies until recently and are likely to expand the market’s size and enable the drug manufacturers to penetrate more into the market.
The companies and academics are working to assess challenges and seek opportunities that could influence IgAN R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition. Major players are involved in developing therapies for IgAN. The launch of emerging therapies will significantly impact the IgAN market. Thus, North America is expected to possess 40% market share for IgA nephropathy market in 2023.
Increasing cases of Kidney Ailments Boosting Growth of IgA Neuropathy Market in Asia Pacific?
Lifestyle changes and sedentary lifestyle contributing to IgA neuropathy market in Asia Pacific
The major factors driving the growth of the market in the Asia region are the rising number of kidney cancer cases and increased R&D expenditure of the pharmaceutical companies. Major countries contributing to kidney cancer cases in Asia are China and Japan. These countries were among the highest cases of kidney cancer worldwide. Furthermore, according to the International Agency for Research on Cancer, in 2018, there were about 148,947 new kidney cancer cases and the mortality was approximately 79,149 cases in Asia.
Furthermore, changes in lifestyle, excessive smoking, increased consumption of alcohol, and a rise in obesity because of sedentary life routines lead to the growing incidence of the disease. Thus, owing to the above factors the Asia-Pacific kidney cancer therapeutics & diagnostics market is expected to significant growth over the forecast period. Owing to the aforementioned reasons, Asia Pacific is expected to possess 35% market share for IgA Neuropathy market in 2023.
A unified Market Research Subscription Platform, built for today's disparate research needs.
Category-Wise Insights
Favorable Reimbursements Policies Surging Inclination Towards Hospitals?
Initiatives by healthcare organizations spurring dependency on hospitals
Owing to the surge in hospitalization, doctors require diagnostic interpretation for further treatment. Usually, diagnostic centers function in association with hospitals; hence, hospitals have their diagnostic setup. Moreover, the ongoing development of healthcare infrastructure is likely to enhance existing hospital facilities, expanding their services and offerings.
Thus, this expansion may boost the demand for products such as kidney function tests, thereby driving the market. In addition, favorable reimbursement scenarios and an increase in the number of initiatives being undertaken by healthcare organizations globally to promote the use of advanced diagnostic tests are also likely to propel segment growth.
Thus, the hospital’s segment is expected to hold 40% of the market share in 2023 for IgA nephropathy market.
Investments in Urine Test Functioning Increasing Growth of Urine Tests for IgA Nephropathy Market?
Frequent requirement for urine testing increasing dependability on urine tests
The urine tests segment is projected to witness significant a CAGR of 7.5% during the forecast years. One of the most frequently used procedures for assessing renal function is urea quantification. Urine, plasma, and serum urea analyses are crucial clinical tests for detecting renal illness and dysfunction. For the diagnosis of pre-renal, renal, and post-renal uremia, urine tests are frequently performed in conjunction with creatinine determination tests. Furthermore, growing investments in the renal function testing industry are also anticipated to support market expansion.
For instance, in January 2020, Sweden-based Elypta AB raised seed financing of USD 7.0 million to provide the first urine test for renal cancer.
Market Competition
Some of the key companies in the IgA Nephropathy therapeutics market include Calliditas Therapeutics AB, Travere Therapeutics, Inc., Omeros Corporation, Novartis Pharmaceuticals, Chinook Therapeutics, Inc., Vera Therapeutics, Inc., Otsuka Pharmaceutical, and others
- In January 2022, Calliditas Therapeutics announced the commercial availability and initial sales of Tarpeyo (budesonide), the first and only FDA approved treatment for IgA nephropathy, in the US. It is indicated for reduction of proteinuria in adults with primary IgA nephropathy at risk of rapid disease progression, generally considered a urine protein-to-creatinine ratio (UPCR) ≥1.5g/g.
- In March 2022, Travere Therapeutics submitted the NDA application for accelerated approval and is expecting the acceptance of application and PUFDA in May 2022.
Report Scope
|
Report Attribute |
Details |
|
Market Value in 2023 |
US$ 41.24 Billion |
|
Market Value in 2033 |
US$ 85 Billion |
|
Growth Rate |
CAGR of 7.5% from 2023 to 2033 |
|
Base Year for Estimation |
2022 |
|
Historical Data |
2017-2022 |
|
Forecast Period |
2023-2033 |
|
Quantitative Units |
Revenue in USD Billion and CAGR from 2023-2033 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
|
Segments Covered |
Region |
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments Profiled in the IgA Nephropathy Market Survey
Diagnosis:
- Iothalamate Clearance Test
- Kidney Biopsy
- Blood Tests
- Urine Tests
Diseases Type:
- Primary IgA Nephropathy
- Secondary IgA Nephropathy
Systems:
- Hematuria
- Proteinuria
- Edema
- Others
Population Type:
- Pediatrics
- Adults
Route of Administration:
- Oral
- Parenteral
- Others
Treatment:
- Medication
- Statin therapy
- Omega-3 fatty acids
- Angiotensin-converting enzyme (ACE) inhibitors
- Angiotensin receptor blockers (ARBs)
- Diuretics
- Immunosuppressants
- Kidney Transplantation
- Others
End Users:
- Hospitals
- Specialty Clinics
- Homecare
- Others
Region:
- North America
- Latin America
- Europe
- South Asia & Pacific
- East Asia
- Middle East & Africa
Frequently Asked Questions
From 2017-2022, the IgA nephropathy market grew at a CAGR of 4.8%
The global IgA nephropathy market is expected to grow with a 7.5% CAGR during 2023-2033.
As of 2033, the IgA nephropathy market is expected to reach US$ 41.24 Billion
The hospital’s segment is expected to hold 40% of the market share in 2023 for IgA nephropathy market.
The urine tests segment is projected to witness significant a CAGR of 7.5% during the forecast years
North America is expected to possess 40% market share for IgA nephropathy market in 2023.
Asia Pacific IgA nephropathy market size is expected to possess 35% market share in 2023.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018-2022 and Forecast, 2023-2033
4.1. Historical Market Size Value (US$ Mn) Analysis, 2018-2022
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2023-2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Diagnosis
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Diagnosis, 2018-2022
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Diagnosis, 2023-2033
5.3.1. Iothalamate Clearance Test
5.3.2. Kidney Biopsy
5.3.3. Blood Tests
5.3.4. Urine Tests
5.4. Y-o-Y Growth Trend Analysis By Diagnosis, 2018-2022
5.5. Absolute $ Opportunity Analysis By Diagnosis, 2023-2033
6. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Disease Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) Analysis By Disease Type, 2018-2022
6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Disease Type, 2023-2033
6.3.1. Primary
6.3.2. Secondary
6.4. Y-o-Y Growth Trend Analysis By Disease Type, 2018-2022
6.5. Absolute $ Opportunity Analysis By Disease Type, 2023-2033
7. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Symptoms
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Mn) Analysis By Symptoms , 2018-2022
7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Symptoms , 2023-2033
7.3.1. Hematuria
7.3.2. Proteinuria
7.3.3. Edema
7.3.4. Others
7.4. Y-o-Y Growth Trend Analysis By Symptoms , 2018-2022
7.5. Absolute $ Opportunity Analysis By Symptoms , 2023-2033
8. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Population Type
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Mn) Analysis By Population Type, 2018-2022
8.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Population Type, 2023-2033
8.3.1. Pediatrics
8.3.2. Adults
8.4. Y-o-Y Growth Trend Analysis By Population Type, 2018-2022
8.5. Absolute $ Opportunity Analysis By Population Type, 2023-2033
9. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Route of Administration
9.1. Introduction / Key Findings
9.2. Historical Market Size Value (US$ Mn) Analysis By Route of Administration, 2018-2022
9.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Route of Administration, 2023-2033
9.3.1. Oral
9.3.2. Parenteral
9.3.3. Others
9.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018-2022
9.5. Absolute $ Opportunity Analysis By Route of Administration, 2023-2033
10. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Treatment
10.1. Introduction / Key Findings
10.2. Historical Market Size Value (US$ Mn) Analysis By Treatment, 2018-2022
10.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Treatment, 2023-2033
10.3.1. Medication
10.3.2. Statin therapy
10.3.3. Omega-3 fatty acids
10.3.4. Angiotensin-converting enzyme (ACE) inhibitors
10.3.5. Angiotensin receptor blockers (ARBs)
10.3.6. Diuretics
10.3.7. Immunosuppressants
10.3.8. Kidney Transplantation
10.3.9. Others
10.4. Y-o-Y Growth Trend Analysis By Treatment, 2018-2022
10.5. Absolute $ Opportunity Analysis By Treatment, 2023-2033
11. Global Market Analysis 2018-2022 and Forecast 2023-2033, By End-Users
11.1. Introduction / Key Findings
11.2. Historical Market Size Value (US$ Mn) Analysis By End-Users, 2018-2022
11.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By End-Users, 2023-2033
11.3.1. Hospitals
11.3.2. Specialty Clinics
11.3.3. Homecare
11.3.4. Others
11.4. Y-o-Y Growth Trend Analysis By End-Users, 2018-2022
11.5. Absolute $ Opportunity Analysis By End-Users, 2023-2033
12. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Region
12.1. Introduction
12.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2018-2022
12.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2023-2033
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. South Asia & Pacific
12.3.5. East Asia
12.3.6. MEA
12.4. Market Attractiveness Analysis By Region
13. North America Market Analysis 2018-2022 and Forecast 2023-2033, By Country
13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
13.2.1. By Country
13.2.1.1. U.S.
13.2.1.2. Canada
13.2.2. By Diagnosis
13.2.3. By Disease Type
13.2.4. By Symptoms
13.2.5. By Population Type
13.2.6. By Route of Administration
13.2.7. By Treatment
13.2.8. By End-Users
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Diagnosis
13.3.3. By Disease Type
13.3.4. By Symptoms
13.3.5. By Population Type
13.3.6. By Route of Administration
13.3.7. By Treatment
13.3.8. By End-Users
13.4. Key Takeaways
14. Latin America Market Analysis 2018-2022 and Forecast 2023-2033, By Country
14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
14.2.1. By Country
14.2.1.1. Brazil
14.2.1.2. Mexico
14.2.1.3. Rest of Latin America
14.2.2. By Diagnosis
14.2.3. By Disease Type
14.2.4. By Symptoms
14.2.5. By Population Type
14.2.6. By Route of Administration
14.2.7. By Treatment
14.2.8. By End-Users
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Diagnosis
14.3.3. By Disease Type
14.3.4. By Symptoms
14.3.5. By Population Type
14.3.6. By Route of Administration
14.3.7. By Treatment
14.3.8. By End-Users
14.4. Key Takeaways
15. Europe Market Analysis 2018-2022 and Forecast 2023-2033, By Country
15.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
15.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
15.2.1. By Country
15.2.1.1. Germany
15.2.1.2. U.K.
15.2.1.3. France
15.2.1.4. Spain
15.2.1.5. Italy
15.2.1.6. Rest of Europe
15.2.2. By Diagnosis
15.2.3. By Disease Type
15.2.4. By Symptoms
15.2.5. By Population Type
15.2.6. By Route of Administration
15.2.7. By Treatment
15.2.8. By End-Users
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Diagnosis
15.3.3. By Disease Type
15.3.4. By Symptoms
15.3.5. By Population Type
15.3.6. By Route of Administration
15.3.7. By Treatment
15.3.8. By End-Users
15.4. Key Takeaways
16. South Asia & Pacific Market Analysis 2018-2022 and Forecast 2023-2033, By Country
16.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
16.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
16.2.1. By Country
16.2.1.1. India
16.2.1.2. Malaysia
16.2.1.3. Singapore
16.2.1.4. Thailand
16.2.1.5. Australia
16.2.1.6. New Zealand
16.2.1.7. Rest of South Asia & Pacific
16.2.2. By Diagnosis
16.2.3. By Disease Type
16.2.4. By Symptoms
16.2.5. By Population Type
16.2.6. By Route of Administration
16.2.7. By Treatment
16.2.8. By End-Users
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Diagnosis
16.3.3. By Disease Type
16.3.4. By Symptoms
16.3.5. By Population Type
16.3.6. By Route of Administration
16.3.7. By Treatment
16.3.8. By End-Users
16.4. Key Takeaways
17. East Asia Market Analysis 2018-2022 and Forecast 2023-2033, By Country
17.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
17.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
17.2.1. By Country
17.2.1.1. China
17.2.1.2. Japan
17.2.1.3. South Korea
17.2.2. By Diagnosis
17.2.3. By Disease Type
17.2.4. By Symptoms
17.2.5. By Population Type
17.2.6. By Route of Administration
17.2.7. By Treatment
17.2.8. By End-Users
17.3. Market Attractiveness Analysis
17.3.1. By Country
17.3.2. By Diagnosis
17.3.3. By Disease Type
17.3.4. By Symptoms
17.3.5. By Population Type
17.3.6. By Route of Administration
17.3.7. By Treatment
17.3.8. By End-Users
17.4. Key Takeaways
18. MEA Market Analysis 2018-2022 and Forecast 2023-2033, By Country
18.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
18.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
18.2.1. By Country
18.2.1.1. GCC Countries
18.2.1.2. South Africa
18.2.1.3. Israel
18.2.1.4. Rest of MEA
18.2.2. By Diagnosis
18.2.3. By Disease Type
18.2.4. By Symptoms
18.2.5. By Population Type
18.2.6. By Route of Administration
18.2.7. By Treatment
18.2.8. By End-Users
18.3. Market Attractiveness Analysis
18.3.1. By Country
18.3.2. By Diagnosis
18.3.3. By Disease Type
18.3.4. By Symptoms
18.3.5. By Population Type
18.3.6. By Route of Administration
18.3.7. By Treatment
18.3.8. By End-Users
18.4. Key Takeaways
19. Key Countries Market Analysis
19.1. U.S.
19.1.1. Pricing Analysis
19.1.2. Market Share Analysis, 2022
19.1.2.1. By Diagnosis
19.1.2.2. By Disease Type
19.1.2.3. By Symptoms
19.1.2.4. By Population Type
19.1.2.5. By Route of Administration
19.1.2.6. By Treatment
19.1.2.7. By End-Users
19.2. Canada
19.2.1. Pricing Analysis
19.2.2. Market Share Analysis, 2022
19.2.2.1. By Diagnosis
19.2.2.2. By Disease Type
19.2.2.3. By Symptoms
19.2.2.4. By Population Type
19.2.2.5. By Route of Administration
19.2.2.6. By Treatment
19.2.2.7. By End-Users
19.3. Brazil
19.3.1. Pricing Analysis
19.3.2. Market Share Analysis, 2022
19.3.2.1. By Diagnosis
19.3.2.2. By Disease Type
19.3.2.3. By Symptoms
19.3.2.4. By Population Type
19.3.2.5. By Route of Administration
19.3.2.6. By Treatment
19.3.2.7. By End-Users
19.4. Mexico
19.4.1. Pricing Analysis
19.4.2. Market Share Analysis, 2022
19.4.2.1. By Diagnosis
19.4.2.2. By Disease Type
19.4.2.3. By Symptoms
19.4.2.4. By Population Type
19.4.2.5. By Route of Administration
19.4.2.6. By Treatment
19.4.2.7. By End-Users
19.5. Germany
19.5.1. Pricing Analysis
19.5.2. Market Share Analysis, 2022
19.5.2.1. By Diagnosis
19.5.2.2. By Disease Type
19.5.2.3. By Symptoms
19.5.2.4. By Population Type
19.5.2.5. By Route of Administration
19.5.2.6. By Treatment
19.5.2.7. By End-Users
19.6. U.K.
19.6.1. Pricing Analysis
19.6.2. Market Share Analysis, 2022
19.6.2.1. By Diagnosis
19.6.2.2. By Disease Type
19.6.2.3. By Symptoms
19.6.2.4. By Population Type
19.6.2.5. By Route of Administration
19.6.2.6. By Treatment
19.6.2.7. By End-Users
19.7. France
19.7.1. Pricing Analysis
19.7.2. Market Share Analysis, 2022
19.7.2.1. By Diagnosis
19.7.2.2. By Disease Type
19.7.2.3. By Symptoms
19.7.2.4. By Population Type
19.7.2.5. By Route of Administration
19.7.2.6. By Treatment
19.7.2.7. By End-Users
19.8. Spain
19.8.1. Pricing Analysis
19.8.2. Market Share Analysis, 2022
19.8.2.1. By Diagnosis
19.8.2.2. By Disease Type
19.8.2.3. By Symptoms
19.8.2.4. By Population Type
19.8.2.5. By Route of Administration
19.8.2.6. By Treatment
19.8.2.7. By End-Users
19.9. Italy
19.9.1. Pricing Analysis
19.9.2. Market Share Analysis, 2022
19.9.2.1. By Diagnosis
19.9.2.2. By Disease Type
19.9.2.3. By Symptoms
19.9.2.4. By Population Type
19.9.2.5. By Route of Administration
19.9.2.6. By Treatment
19.9.2.7. By End-Users
19.10. India
19.10.1. Pricing Analysis
19.10.2. Market Share Analysis, 2022
19.10.2.1. By Diagnosis
19.10.2.2. By Disease Type
19.10.2.3. By Symptoms
19.10.2.4. By Population Type
19.10.2.5. By Route of Administration
19.10.2.6. By Treatment
19.10.2.7. By End-Users
19.11. Malaysia
19.11.1. Pricing Analysis
19.11.2. Market Share Analysis, 2022
19.11.2.1. By Diagnosis
19.11.2.2. By Disease Type
19.11.2.3. By Symptoms
19.11.2.4. By Population Type
19.11.2.5. By Route of Administration
19.11.2.6. By Treatment
19.11.2.7. By End-Users
19.12. Singapore
19.12.1. Pricing Analysis
19.12.2. Market Share Analysis, 2022
19.12.2.1. By Diagnosis
19.12.2.2. By Disease Type
19.12.2.3. By Symptoms
19.12.2.4. By Population Type
19.12.2.5. By Route of Administration
19.12.2.6. By Treatment
19.12.2.7. By End-Users
19.13. Thailand
19.13.1. Pricing Analysis
19.13.2. Market Share Analysis, 2022
19.13.2.1. By Diagnosis
19.13.2.2. By Disease Type
19.13.2.3. By Symptoms
19.13.2.4. By Population Type
19.13.2.5. By Route of Administration
19.13.2.6. By Treatment
19.13.2.7. By End-Users
19.14. Australia
19.14.1. Pricing Analysis
19.14.2. Market Share Analysis, 2022
19.14.2.1. By Diagnosis
19.14.2.2. By Disease Type
19.14.2.3. By Symptoms
19.14.2.4. By Population Type
19.14.2.5. By Route of Administration
19.14.2.6. By Treatment
19.14.2.7. By End-Users
19.15. New Zealand
19.15.1. Pricing Analysis
19.15.2. Market Share Analysis, 2022
19.15.2.1. By Diagnosis
19.15.2.2. By Disease Type
19.15.2.3. By Symptoms
19.15.2.4. By Population Type
19.15.2.5. By Route of Administration
19.15.2.6. By Treatment
19.15.2.7. By End-Users
19.16. China
19.16.1. Pricing Analysis
19.16.2. Market Share Analysis, 2022
19.16.2.1. By Diagnosis
19.16.2.2. By Disease Type
19.16.2.3. By Symptoms
19.16.2.4. By Population Type
19.16.2.5. By Route of Administration
19.16.2.6. By Treatment
19.16.2.7. By End-Users
19.17. Japan
19.17.1. Pricing Analysis
19.17.2. Market Share Analysis, 2022
19.17.2.1. By Diagnosis
19.17.2.2. By Disease Type
19.17.2.3. By Symptoms
19.17.2.4. By Population Type
19.17.2.5. By Route of Administration
19.17.2.6. By Treatment
19.17.2.7. By End-Users
19.18. South Korea
19.18.1. Pricing Analysis
19.18.2. Market Share Analysis, 2022
19.18.2.1. By Diagnosis
19.18.2.2. By Disease Type
19.18.2.3. By Symptoms
19.18.2.4. By Population Type
19.18.2.5. By Route of Administration
19.18.2.6. By Treatment
19.18.2.7. By End-Users
19.19. GCC Countries
19.19.1. Pricing Analysis
19.19.2. Market Share Analysis, 2022
19.19.2.1. By Diagnosis
19.19.2.2. By Disease Type
19.19.2.3. By Symptoms
19.19.2.4. By Population Type
19.19.2.5. By Route of Administration
19.19.2.6. By Treatment
19.19.2.7. By End-Users
19.20. South Africa
19.20.1. Pricing Analysis
19.20.2. Market Share Analysis, 2022
19.20.2.1. By Diagnosis
19.20.2.2. By Disease Type
19.20.2.3. By Symptoms
19.20.2.4. By Population Type
19.20.2.5. By Route of Administration
19.20.2.6. By Treatment
19.20.2.7. By End-Users
19.21. Israel
19.21.1. Pricing Analysis
19.21.2. Market Share Analysis, 2022
19.21.2.1. By Diagnosis
19.21.2.2. By Disease Type
19.21.2.3. By Symptoms
19.21.2.4. By Population Type
19.21.2.5. By Route of Administration
19.21.2.6. By Treatment
19.21.2.7. By End-Users
20. Market Structure Analysis
20.1. Competition Dashboard
20.2. Competition Benchmarking
20.3. Market Share Analysis of Top Players
20.3.1. By Regional
20.3.2. By Diagnosis
20.3.3. By Disease Type
20.3.4. By Symptoms
20.3.5. By Population Type
20.3.6. By Route of Administration
20.3.7. By Treatment
20.3.8. By End-Users
21. Competition Analysis
21.1. Competition Deep Dive
21.1.1. Calliditas Therapeutics AB
21.1.1.1. Overview
21.1.1.2. Product Portfolio
21.1.1.3. Profitability by Market Segments
21.1.1.4. Sales Footprint
21.1.1.5. Strategy Overview
21.1.1.5.1. Marketing Strategy
21.1.2. Travere Therapeutics, Inc.
21.1.2.1. Overview
21.1.2.2. Product Portfolio
21.1.2.3. Profitability by Market Segments
21.1.2.4. Sales Footprint
21.1.2.5. Strategy Overview
21.1.2.5.1. Marketing Strategy
21.1.3. Omeros Corporation
21.1.3.1. Overview
21.1.3.2. Product Portfolio
21.1.3.3. Profitability by Market Segments
21.1.3.4. Sales Footprint
21.1.3.5. Strategy Overview
21.1.3.5.1. Marketing Strategy
21.1.4. Novartis Pharmaceuticals
21.1.4.1. Overview
21.1.4.2. Product Portfolio
21.1.4.3. Profitability by Market Segments
21.1.4.4. Sales Footprint
21.1.4.5. Strategy Overview
21.1.4.5.1. Marketing Strategy
21.1.5. Chinook Therapeutics, Inc.
21.1.5.1. Overview
21.1.5.2. Product Portfolio
21.1.5.3. Profitability by Market Segments
21.1.5.4. Sales Footprint
21.1.5.5. Strategy Overview
21.1.5.5.1. Marketing Strategy
21.1.6. Vera Therapeutics, Inc.
21.1.6.1. Overview
21.1.6.2. Product Portfolio
21.1.6.3. Profitability by Market Segments
21.1.6.4. Sales Footprint
21.1.6.5. Strategy Overview
21.1.6.5.1. Marketing Strategy
21.1.7. Otsuka Pharmaceutical
21.1.7.1. Overview
21.1.7.2. Product Portfolio
21.1.7.3. Profitability by Market Segments
21.1.7.4. Sales Footprint
21.1.7.5. Strategy Overview
21.1.7.5.1. Marketing Strategy
21.1.8. Alembic Pharmaceuticals Limited
21.1.8.1. Overview
21.1.8.2. Product Portfolio
21.1.8.3. Profitability by Market Segments
21.1.8.4. Sales Footprint
21.1.8.5. Strategy Overview
21.1.8.5.1. Marketing Strategy
21.1.9. Teva Pharmaceutical Industries Ltd.
21.1.9.1. Overview
21.1.9.2. Product Portfolio
21.1.9.3. Profitability by Market Segments
21.1.9.4. Sales Footprint
21.1.9.5. Strategy Overview
21.1.9.5.1. Marketing Strategy
21.1.10. Johnson & Johnson Private Limited
21.1.10.1. Overview
21.1.10.2. Product Portfolio
21.1.10.3. Profitability by Market Segments
21.1.10.4. Sales Footprint
21.1.10.5. Strategy Overview
21.1.10.5.1. Marketing Strategy
22. Assumptions & Acronyms Used
23. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Market Value (US$ Mn) Forecast by Region, 2018-2033
Table 2: Global Market Value (US$ Mn) Forecast by Diagnosis, 2018-2033
Table 3: Global Market Value (US$ Mn) Forecast by Disease Type, 2018-2033
Table 4: Global Market Value (US$ Mn) Forecast by Symptoms , 2018-2033
Table 5: Global Market Value (US$ Mn) Forecast by Population Type, 2018-2033
Table 6: Global Market Value (US$ Mn) Forecast by Route of Administration, 2018-2033
Table 7: Global Market Value (US$ Mn) Forecast by Treatment, 2018-2033
Table 8: Global Market Value (US$ Mn) Forecast by End-Users, 2018-2033
Table 9: North America Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 10: North America Market Value (US$ Mn) Forecast by Diagnosis, 2018-2033
Table 11: North America Market Value (US$ Mn) Forecast by Disease Type, 2018-2033
Table 12: North America Market Value (US$ Mn) Forecast by Symptoms , 2018-2033
Table 13: North America Market Value (US$ Mn) Forecast by Population Type, 2018-2033
Table 14: North America Market Value (US$ Mn) Forecast by Route of Administration, 2018-2033
Table 15: North America Market Value (US$ Mn) Forecast by Treatment, 2018-2033
Table 16: North America Market Value (US$ Mn) Forecast by End-Users, 2018-2033
Table 17: Latin America Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 18: Latin America Market Value (US$ Mn) Forecast by Diagnosis, 2018-2033
Table 19: Latin America Market Value (US$ Mn) Forecast by Disease Type, 2018-2033
Table 20: Latin America Market Value (US$ Mn) Forecast by Symptoms , 2018-2033
Table 21: Latin America Market Value (US$ Mn) Forecast by Population Type, 2018-2033
Table 22: Latin America Market Value (US$ Mn) Forecast by Route of Administration, 2018-2033
Table 23: Latin America Market Value (US$ Mn) Forecast by Treatment, 2018-2033
Table 24: Latin America Market Value (US$ Mn) Forecast by End-Users, 2018-2033
Table 25: Europe Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 26: Europe Market Value (US$ Mn) Forecast by Diagnosis, 2018-2033
Table 27: Europe Market Value (US$ Mn) Forecast by Disease Type, 2018-2033
Table 28: Europe Market Value (US$ Mn) Forecast by Symptoms , 2018-2033
Table 29: Europe Market Value (US$ Mn) Forecast by Population Type, 2018-2033
Table 30: Europe Market Value (US$ Mn) Forecast by Route of Administration, 2018-2033
Table 31: Europe Market Value (US$ Mn) Forecast by Treatment, 2018-2033
Table 32: Europe Market Value (US$ Mn) Forecast by End-Users, 2018-2033
Table 33: South Asia & Pacific Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 34: South Asia & Pacific Market Value (US$ Mn) Forecast by Diagnosis, 2018-2033
Table 35: South Asia & Pacific Market Value (US$ Mn) Forecast by Disease Type, 2018-2033
Table 36: South Asia & Pacific Market Value (US$ Mn) Forecast by Symptoms , 2018-2033
Table 37: South Asia & Pacific Market Value (US$ Mn) Forecast by Population Type, 2018-2033
Table 38: South Asia & Pacific Market Value (US$ Mn) Forecast by Route of Administration, 2018-2033
Table 39: South Asia & Pacific Market Value (US$ Mn) Forecast by Treatment, 2018-2033
Table 40: South Asia & Pacific Market Value (US$ Mn) Forecast by End-Users, 2018-2033
Table 41: East Asia Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 42: East Asia Market Value (US$ Mn) Forecast by Diagnosis, 2018-2033
Table 43: East Asia Market Value (US$ Mn) Forecast by Disease Type, 2018-2033
Table 44: East Asia Market Value (US$ Mn) Forecast by Symptoms , 2018-2033
Table 45: East Asia Market Value (US$ Mn) Forecast by Population Type, 2018-2033
Table 46: East Asia Market Value (US$ Mn) Forecast by Route of Administration, 2018-2033
Table 47: East Asia Market Value (US$ Mn) Forecast by Treatment, 2018-2033
Table 48: East Asia Market Value (US$ Mn) Forecast by End-Users, 2018-2033
Table 49: MEA Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 50: MEA Market Value (US$ Mn) Forecast by Diagnosis, 2018-2033
Table 51: MEA Market Value (US$ Mn) Forecast by Disease Type, 2018-2033
Table 52: MEA Market Value (US$ Mn) Forecast by Symptoms , 2018-2033
Table 53: MEA Market Value (US$ Mn) Forecast by Population Type, 2018-2033
Table 54: MEA Market Value (US$ Mn) Forecast by Route of Administration, 2018-2033
Table 55: MEA Market Value (US$ Mn) Forecast by Treatment, 2018-2033
Table 56: MEA Market Value (US$ Mn) Forecast by End-Users, 2018-2033
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ Mn) by Diagnosis, 2023-2033
Figure 2: Global Market Value (US$ Mn) by Disease Type, 2023-2033
Figure 3: Global Market Value (US$ Mn) by Symptoms , 2023-2033
Figure 4: Global Market Value (US$ Mn) by Population Type, 2023-2033
Figure 5: Global Market Value (US$ Mn) by Route of Administration, 2023-2033
Figure 6: Global Market Value (US$ Mn) by Treatment, 2023-2033
Figure 7: Global Market Value (US$ Mn) by End-Users, 2023-2033
Figure 8: Global Market Value (US$ Mn) by Region, 2023-2033
Figure 9: Global Market Value (US$ Mn) Analysis by Region, 2018-2033
Figure 10: Global Market Value Share (%) and BPS Analysis by Region, 2023-2033
Figure 11: Global Market Y-o-Y Growth (%) Projections by Region, 2023-2033
Figure 12: Global Market Value (US$ Mn) Analysis by Diagnosis, 2018-2033
Figure 13: Global Market Value Share (%) and BPS Analysis by Diagnosis, 2023-2033
Figure 14: Global Market Y-o-Y Growth (%) Projections by Diagnosis, 2023-2033
Figure 15: Global Market Value (US$ Mn) Analysis by Disease Type, 2018-2033
Figure 16: Global Market Value Share (%) and BPS Analysis by Disease Type, 2023-2033
Figure 17: Global Market Y-o-Y Growth (%) Projections by Disease Type, 2023-2033
Figure 18: Global Market Value (US$ Mn) Analysis by Symptoms , 2018-2033
Figure 19: Global Market Value Share (%) and BPS Analysis by Symptoms , 2023-2033
Figure 20: Global Market Y-o-Y Growth (%) Projections by Symptoms , 2023-2033
Figure 21: Global Market Value (US$ Mn) Analysis by Population Type, 2018-2033
Figure 22: Global Market Value Share (%) and BPS Analysis by Population Type, 2023-2033
Figure 23: Global Market Y-o-Y Growth (%) Projections by Population Type, 2023-2033
Figure 24: Global Market Value (US$ Mn) Analysis by Route of Administration, 2018-2033
Figure 25: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2023-2033
Figure 26: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2023-2033
Figure 27: Global Market Value (US$ Mn) Analysis by Treatment, 2018-2033
Figure 28: Global Market Value Share (%) and BPS Analysis by Treatment, 2023-2033
Figure 29: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023-2033
Figure 30: Global Market Value (US$ Mn) Analysis by End-Users, 2018-2033
Figure 31: Global Market Value Share (%) and BPS Analysis by End-Users, 2023-2033
Figure 32: Global Market Y-o-Y Growth (%) Projections by End-Users, 2023-2033
Figure 33: Global Market Attractiveness by Diagnosis, 2023-2033
Figure 34: Global Market Attractiveness by Disease Type, 2023-2033
Figure 35: Global Market Attractiveness by Symptoms , 2023-2033
Figure 36: Global Market Attractiveness by Population Type, 2023-2033
Figure 37: Global Market Attractiveness by Route of Administration, 2023-2033
Figure 38: Global Market Attractiveness by Treatment, 2023-2033
Figure 39: Global Market Attractiveness by End-Users, 2023-2033
Figure 40: Global Market Attractiveness by Region, 2023-2033
Figure 41: North America Market Value (US$ Mn) by Diagnosis, 2023-2033
Figure 42: North America Market Value (US$ Mn) by Disease Type, 2023-2033
Figure 43: North America Market Value (US$ Mn) by Symptoms , 2023-2033
Figure 44: North America Market Value (US$ Mn) by Population Type, 2023-2033
Figure 45: North America Market Value (US$ Mn) by Route of Administration, 2023-2033
Figure 46: North America Market Value (US$ Mn) by Treatment, 2023-2033
Figure 47: North America Market Value (US$ Mn) by End-Users, 2023-2033
Figure 48: North America Market Value (US$ Mn) by Country, 2023-2033
Figure 49: North America Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 50: North America Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 51: North America Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 52: North America Market Value (US$ Mn) Analysis by Diagnosis, 2018-2033
Figure 53: North America Market Value Share (%) and BPS Analysis by Diagnosis, 2023-2033
Figure 54: North America Market Y-o-Y Growth (%) Projections by Diagnosis, 2023-2033
Figure 55: North America Market Value (US$ Mn) Analysis by Disease Type, 2018-2033
Figure 56: North America Market Value Share (%) and BPS Analysis by Disease Type, 2023-2033
Figure 57: North America Market Y-o-Y Growth (%) Projections by Disease Type, 2023-2033
Figure 58: North America Market Value (US$ Mn) Analysis by Symptoms , 2018-2033
Figure 59: North America Market Value Share (%) and BPS Analysis by Symptoms , 2023-2033
Figure 60: North America Market Y-o-Y Growth (%) Projections by Symptoms , 2023-2033
Figure 61: North America Market Value (US$ Mn) Analysis by Population Type, 2018-2033
Figure 62: North America Market Value Share (%) and BPS Analysis by Population Type, 2023-2033
Figure 63: North America Market Y-o-Y Growth (%) Projections by Population Type, 2023-2033
Figure 64: North America Market Value (US$ Mn) Analysis by Route of Administration, 2018-2033
Figure 65: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2023-2033
Figure 66: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023-2033
Figure 67: North America Market Value (US$ Mn) Analysis by Treatment, 2018-2033
Figure 68: North America Market Value Share (%) and BPS Analysis by Treatment, 2023-2033
Figure 69: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023-2033
Figure 70: North America Market Value (US$ Mn) Analysis by End-Users, 2018-2033
Figure 71: North America Market Value Share (%) and BPS Analysis by End-Users, 2023-2033
Figure 72: North America Market Y-o-Y Growth (%) Projections by End-Users, 2023-2033
Figure 73: North America Market Attractiveness by Diagnosis, 2023-2033
Figure 74: North America Market Attractiveness by Disease Type, 2023-2033
Figure 75: North America Market Attractiveness by Symptoms , 2023-2033
Figure 76: North America Market Attractiveness by Population Type, 2023-2033
Figure 77: North America Market Attractiveness by Route of Administration, 2023-2033
Figure 78: North America Market Attractiveness by Treatment, 2023-2033
Figure 79: North America Market Attractiveness by End-Users, 2023-2033
Figure 80: North America Market Attractiveness by Country, 2023-2033
Figure 81: Latin America Market Value (US$ Mn) by Diagnosis, 2023-2033
Figure 82: Latin America Market Value (US$ Mn) by Disease Type, 2023-2033
Figure 83: Latin America Market Value (US$ Mn) by Symptoms , 2023-2033
Figure 84: Latin America Market Value (US$ Mn) by Population Type, 2023-2033
Figure 85: Latin America Market Value (US$ Mn) by Route of Administration, 2023-2033
Figure 86: Latin America Market Value (US$ Mn) by Treatment, 2023-2033
Figure 87: Latin America Market Value (US$ Mn) by End-Users, 2023-2033
Figure 88: Latin America Market Value (US$ Mn) by Country, 2023-2033
Figure 89: Latin America Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 90: Latin America Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 91: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 92: Latin America Market Value (US$ Mn) Analysis by Diagnosis, 2018-2033
Figure 93: Latin America Market Value Share (%) and BPS Analysis by Diagnosis, 2023-2033
Figure 94: Latin America Market Y-o-Y Growth (%) Projections by Diagnosis, 2023-2033
Figure 95: Latin America Market Value (US$ Mn) Analysis by Disease Type, 2018-2033
Figure 96: Latin America Market Value Share (%) and BPS Analysis by Disease Type, 2023-2033
Figure 97: Latin America Market Y-o-Y Growth (%) Projections by Disease Type, 2023-2033
Figure 98: Latin America Market Value (US$ Mn) Analysis by Symptoms , 2018-2033
Figure 99: Latin America Market Value Share (%) and BPS Analysis by Symptoms , 2023-2033
Figure 100: Latin America Market Y-o-Y Growth (%) Projections by Symptoms , 2023-2033
Figure 101: Latin America Market Value (US$ Mn) Analysis by Population Type, 2018-2033
Figure 102: Latin America Market Value Share (%) and BPS Analysis by Population Type, 2023-2033
Figure 103: Latin America Market Y-o-Y Growth (%) Projections by Population Type, 2023-2033
Figure 104: Latin America Market Value (US$ Mn) Analysis by Route of Administration, 2018-2033
Figure 105: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2023-2033
Figure 106: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023-2033
Figure 107: Latin America Market Value (US$ Mn) Analysis by Treatment, 2018-2033
Figure 108: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023-2033
Figure 109: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023-2033
Figure 110: Latin America Market Value (US$ Mn) Analysis by End-Users, 2018-2033
Figure 111: Latin America Market Value Share (%) and BPS Analysis by End-Users, 2023-2033
Figure 112: Latin America Market Y-o-Y Growth (%) Projections by End-Users, 2023-2033
Figure 113: Latin America Market Attractiveness by Diagnosis, 2023-2033
Figure 114: Latin America Market Attractiveness by Disease Type, 2023-2033
Figure 115: Latin America Market Attractiveness by Symptoms , 2023-2033
Figure 116: Latin America Market Attractiveness by Population Type, 2023-2033
Figure 117: Latin America Market Attractiveness by Route of Administration, 2023-2033
Figure 118: Latin America Market Attractiveness by Treatment, 2023-2033
Figure 119: Latin America Market Attractiveness by End-Users, 2023-2033
Figure 120: Latin America Market Attractiveness by Country, 2023-2033
Figure 121: Europe Market Value (US$ Mn) by Diagnosis, 2023-2033
Figure 122: Europe Market Value (US$ Mn) by Disease Type, 2023-2033
Figure 123: Europe Market Value (US$ Mn) by Symptoms , 2023-2033
Figure 124: Europe Market Value (US$ Mn) by Population Type, 2023-2033
Figure 125: Europe Market Value (US$ Mn) by Route of Administration, 2023-2033
Figure 126: Europe Market Value (US$ Mn) by Treatment, 2023-2033
Figure 127: Europe Market Value (US$ Mn) by End-Users, 2023-2033
Figure 128: Europe Market Value (US$ Mn) by Country, 2023-2033
Figure 129: Europe Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 130: Europe Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 131: Europe Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 132: Europe Market Value (US$ Mn) Analysis by Diagnosis, 2018-2033
Figure 133: Europe Market Value Share (%) and BPS Analysis by Diagnosis, 2023-2033
Figure 134: Europe Market Y-o-Y Growth (%) Projections by Diagnosis, 2023-2033
Figure 135: Europe Market Value (US$ Mn) Analysis by Disease Type, 2018-2033
Figure 136: Europe Market Value Share (%) and BPS Analysis by Disease Type, 2023-2033
Figure 137: Europe Market Y-o-Y Growth (%) Projections by Disease Type, 2023-2033
Figure 138: Europe Market Value (US$ Mn) Analysis by Symptoms , 2018-2033
Figure 139: Europe Market Value Share (%) and BPS Analysis by Symptoms , 2023-2033
Figure 140: Europe Market Y-o-Y Growth (%) Projections by Symptoms , 2023-2033
Figure 141: Europe Market Value (US$ Mn) Analysis by Population Type, 2018-2033
Figure 142: Europe Market Value Share (%) and BPS Analysis by Population Type, 2023-2033
Figure 143: Europe Market Y-o-Y Growth (%) Projections by Population Type, 2023-2033
Figure 144: Europe Market Value (US$ Mn) Analysis by Route of Administration, 2018-2033
Figure 145: Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2023-2033
Figure 146: Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2023-2033
Figure 147: Europe Market Value (US$ Mn) Analysis by Treatment, 2018-2033
Figure 148: Europe Market Value Share (%) and BPS Analysis by Treatment, 2023-2033
Figure 149: Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023-2033
Figure 150: Europe Market Value (US$ Mn) Analysis by End-Users, 2018-2033
Figure 151: Europe Market Value Share (%) and BPS Analysis by End-Users, 2023-2033
Figure 152: Europe Market Y-o-Y Growth (%) Projections by End-Users, 2023-2033
Figure 153: Europe Market Attractiveness by Diagnosis, 2023-2033
Figure 154: Europe Market Attractiveness by Disease Type, 2023-2033
Figure 155: Europe Market Attractiveness by Symptoms , 2023-2033
Figure 156: Europe Market Attractiveness by Population Type, 2023-2033
Figure 157: Europe Market Attractiveness by Route of Administration, 2023-2033
Figure 158: Europe Market Attractiveness by Treatment, 2023-2033
Figure 159: Europe Market Attractiveness by End-Users, 2023-2033
Figure 160: Europe Market Attractiveness by Country, 2023-2033
Figure 161: South Asia & Pacific Market Value (US$ Mn) by Diagnosis, 2023-2033
Figure 162: South Asia & Pacific Market Value (US$ Mn) by Disease Type, 2023-2033
Figure 163: South Asia & Pacific Market Value (US$ Mn) by Symptoms , 2023-2033
Figure 164: South Asia & Pacific Market Value (US$ Mn) by Population Type, 2023-2033
Figure 165: South Asia & Pacific Market Value (US$ Mn) by Route of Administration, 2023-2033
Figure 166: South Asia & Pacific Market Value (US$ Mn) by Treatment, 2023-2033
Figure 167: South Asia & Pacific Market Value (US$ Mn) by End-Users, 2023-2033
Figure 168: South Asia & Pacific Market Value (US$ Mn) by Country, 2023-2033
Figure 169: South Asia & Pacific Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 170: South Asia & Pacific Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 171: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 172: South Asia & Pacific Market Value (US$ Mn) Analysis by Diagnosis, 2018-2033
Figure 173: South Asia & Pacific Market Value Share (%) and BPS Analysis by Diagnosis, 2023-2033
Figure 174: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Diagnosis, 2023-2033
Figure 175: South Asia & Pacific Market Value (US$ Mn) Analysis by Disease Type, 2018-2033
Figure 176: South Asia & Pacific Market Value Share (%) and BPS Analysis by Disease Type, 2023-2033
Figure 177: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Disease Type, 2023-2033
Figure 178: South Asia & Pacific Market Value (US$ Mn) Analysis by Symptoms , 2018-2033
Figure 179: South Asia & Pacific Market Value Share (%) and BPS Analysis by Symptoms , 2023-2033
Figure 180: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Symptoms , 2023-2033
Figure 181: South Asia & Pacific Market Value (US$ Mn) Analysis by Population Type, 2018-2033
Figure 182: South Asia & Pacific Market Value Share (%) and BPS Analysis by Population Type, 2023-2033
Figure 183: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Population Type, 2023-2033
Figure 184: South Asia & Pacific Market Value (US$ Mn) Analysis by Route of Administration, 2018-2033
Figure 185: South Asia & Pacific Market Value Share (%) and BPS Analysis by Route of Administration, 2023-2033
Figure 186: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Route of Administration, 2023-2033
Figure 187: South Asia & Pacific Market Value (US$ Mn) Analysis by Treatment, 2018-2033
Figure 188: South Asia & Pacific Market Value Share (%) and BPS Analysis by Treatment, 2023-2033
Figure 189: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Treatment, 2023-2033
Figure 190: South Asia & Pacific Market Value (US$ Mn) Analysis by End-Users, 2018-2033
Figure 191: South Asia & Pacific Market Value Share (%) and BPS Analysis by End-Users, 2023-2033
Figure 192: South Asia & Pacific Market Y-o-Y Growth (%) Projections by End-Users, 2023-2033
Figure 193: South Asia & Pacific Market Attractiveness by Diagnosis, 2023-2033
Figure 194: South Asia & Pacific Market Attractiveness by Disease Type, 2023-2033
Figure 195: South Asia & Pacific Market Attractiveness by Symptoms , 2023-2033
Figure 196: South Asia & Pacific Market Attractiveness by Population Type, 2023-2033
Figure 197: South Asia & Pacific Market Attractiveness by Route of Administration, 2023-2033
Figure 198: South Asia & Pacific Market Attractiveness by Treatment, 2023-2033
Figure 199: South Asia & Pacific Market Attractiveness by End-Users, 2023-2033
Figure 200: South Asia & Pacific Market Attractiveness by Country, 2023-2033
Figure 201: East Asia Market Value (US$ Mn) by Diagnosis, 2023-2033
Figure 202: East Asia Market Value (US$ Mn) by Disease Type, 2023-2033
Figure 203: East Asia Market Value (US$ Mn) by Symptoms , 2023-2033
Figure 204: East Asia Market Value (US$ Mn) by Population Type, 2023-2033
Figure 205: East Asia Market Value (US$ Mn) by Route of Administration, 2023-2033
Figure 206: East Asia Market Value (US$ Mn) by Treatment, 2023-2033
Figure 207: East Asia Market Value (US$ Mn) by End-Users, 2023-2033
Figure 208: East Asia Market Value (US$ Mn) by Country, 2023-2033
Figure 209: East Asia Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 210: East Asia Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 211: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 212: East Asia Market Value (US$ Mn) Analysis by Diagnosis, 2018-2033
Figure 213: East Asia Market Value Share (%) and BPS Analysis by Diagnosis, 2023-2033
Figure 214: East Asia Market Y-o-Y Growth (%) Projections by Diagnosis, 2023-2033
Figure 215: East Asia Market Value (US$ Mn) Analysis by Disease Type, 2018-2033
Figure 216: East Asia Market Value Share (%) and BPS Analysis by Disease Type, 2023-2033
Figure 217: East Asia Market Y-o-Y Growth (%) Projections by Disease Type, 2023-2033
Figure 218: East Asia Market Value (US$ Mn) Analysis by Symptoms , 2018-2033
Figure 219: East Asia Market Value Share (%) and BPS Analysis by Symptoms , 2023-2033
Figure 220: East Asia Market Y-o-Y Growth (%) Projections by Symptoms , 2023-2033
Figure 221: East Asia Market Value (US$ Mn) Analysis by Population Type, 2018-2033
Figure 222: East Asia Market Value Share (%) and BPS Analysis by Population Type, 2023-2033
Figure 223: East Asia Market Y-o-Y Growth (%) Projections by Population Type, 2023-2033
Figure 224: East Asia Market Value (US$ Mn) Analysis by Route of Administration, 2018-2033
Figure 225: East Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2023-2033
Figure 226: East Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2023-2033
Figure 227: East Asia Market Value (US$ Mn) Analysis by Treatment, 2018-2033
Figure 228: East Asia Market Value Share (%) and BPS Analysis by Treatment, 2023-2033
Figure 229: East Asia Market Y-o-Y Growth (%) Projections by Treatment, 2023-2033
Figure 230: East Asia Market Value (US$ Mn) Analysis by End-Users, 2018-2033
Figure 231: East Asia Market Value Share (%) and BPS Analysis by End-Users, 2023-2033
Figure 232: East Asia Market Y-o-Y Growth (%) Projections by End-Users, 2023-2033
Figure 233: East Asia Market Attractiveness by Diagnosis, 2023-2033
Figure 234: East Asia Market Attractiveness by Disease Type, 2023-2033
Figure 235: East Asia Market Attractiveness by Symptoms , 2023-2033
Figure 236: East Asia Market Attractiveness by Population Type, 2023-2033
Figure 237: East Asia Market Attractiveness by Route of Administration, 2023-2033
Figure 238: East Asia Market Attractiveness by Treatment, 2023-2033
Figure 239: East Asia Market Attractiveness by End-Users, 2023-2033
Figure 240: East Asia Market Attractiveness by Country, 2023-2033
Figure 241: MEA Market Value (US$ Mn) by Diagnosis, 2023-2033
Figure 242: MEA Market Value (US$ Mn) by Disease Type, 2023-2033
Figure 243: MEA Market Value (US$ Mn) by Symptoms , 2023-2033
Figure 244: MEA Market Value (US$ Mn) by Population Type, 2023-2033
Figure 245: MEA Market Value (US$ Mn) by Route of Administration, 2023-2033
Figure 246: MEA Market Value (US$ Mn) by Treatment, 2023-2033
Figure 247: MEA Market Value (US$ Mn) by End-Users, 2023-2033
Figure 248: MEA Market Value (US$ Mn) by Country, 2023-2033
Figure 249: MEA Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 250: MEA Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 251: MEA Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 252: MEA Market Value (US$ Mn) Analysis by Diagnosis, 2018-2033
Figure 253: MEA Market Value Share (%) and BPS Analysis by Diagnosis, 2023-2033
Figure 254: MEA Market Y-o-Y Growth (%) Projections by Diagnosis, 2023-2033
Figure 255: MEA Market Value (US$ Mn) Analysis by Disease Type, 2018-2033
Figure 256: MEA Market Value Share (%) and BPS Analysis by Disease Type, 2023-2033
Figure 257: MEA Market Y-o-Y Growth (%) Projections by Disease Type, 2023-2033
Figure 258: MEA Market Value (US$ Mn) Analysis by Symptoms , 2018-2033
Figure 259: MEA Market Value Share (%) and BPS Analysis by Symptoms , 2023-2033
Figure 260: MEA Market Y-o-Y Growth (%) Projections by Symptoms , 2023-2033
Figure 261: MEA Market Value (US$ Mn) Analysis by Population Type, 2018-2033
Figure 262: MEA Market Value Share (%) and BPS Analysis by Population Type, 2023-2033
Figure 263: MEA Market Y-o-Y Growth (%) Projections by Population Type, 2023-2033
Figure 264: MEA Market Value (US$ Mn) Analysis by Route of Administration, 2018-2033
Figure 265: MEA Market Value Share (%) and BPS Analysis by Route of Administration, 2023-2033
Figure 266: MEA Market Y-o-Y Growth (%) Projections by Route of Administration, 2023-2033
Figure 267: MEA Market Value (US$ Mn) Analysis by Treatment, 2018-2033
Figure 268: MEA Market Value Share (%) and BPS Analysis by Treatment, 2023-2033
Figure 269: MEA Market Y-o-Y Growth (%) Projections by Treatment, 2023-2033
Figure 270: MEA Market Value (US$ Mn) Analysis by End-Users, 2018-2033
Figure 271: MEA Market Value Share (%) and BPS Analysis by End-Users, 2023-2033
Figure 272: MEA Market Y-o-Y Growth (%) Projections by End-Users, 2023-2033
Figure 273: MEA Market Attractiveness by Diagnosis, 2023-2033
Figure 274: MEA Market Attractiveness by Disease Type, 2023-2033
Figure 275: MEA Market Attractiveness by Symptoms , 2023-2033
Figure 276: MEA Market Attractiveness by Population Type, 2023-2033
Figure 277: MEA Market Attractiveness by Route of Administration, 2023-2033
Figure 278: MEA Market Attractiveness by Treatment, 2023-2033
Figure 279: MEA Market Attractiveness by End-Users, 2023-2033
Figure 280: MEA Market Attractiveness by Country, 2023-2033
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
